CPIX
CUMBERLAND PHARMACEUTICALS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.70
−6.69%Year over year
Reported trailing growth
- Revenue
- -25.7%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- -89.5%
Forward estimates
Based on analyst estimates
- Revenue
- +34.7%
- EBITDA
- +32.9%
- EPS
- +63.6%
Three-year CAGR
- Revenue
- +2.0%
- EBITDA
- +107.1%
- EBIT
- +56.6%
- Net income
- +56.2%
- EPS
- +58.7%
- Free cash flow
- -8.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026